title: Eradication of a chronic wound and driveline infection after redo-LVAD implantation.
abstract: A 48 year old patient with dilated cardiomyopathy and chronic acne inversa underwent implantation of a LVAD system (Heartmate II, Thoratec, USA) March 2011. During 2011 and 2012 the patient was repeatedly readmitted for treatment of driveline infection with MRSA. Colonization was controlled with Linezolid and Rifampicin however reoccurred after discontinuation. In August 2012 the LVAD-system was exchanged due to pump dysfunction (HVAD, HeartWare Inc., USA). Postoperatively, the patient presented with ascites which secreted through the driveline exit. Consequently, the abdominal wall was surgically corrected to prevent exit of peritoneal fluid through the driveline, and the patient was discharged with sterile wound swabs. However 6 weeks after discharge the driveline exit wound started secreting pus showing abundant growth of multi resistant staphylococcus aureus (MRSA). With clinical signs of increasing liver failure with regular need for paracentesis, and clinical signs of local infection, a CT scan of the abdomen was performed revealing an enrichment of contrast medium along the driveline and an abscess-like formation on the abdominal wall. Patient was admitted receiving regular dose Daptomycin and Rifampicin. The latter was discontinued after ten days. The abscess, surrounding driveline exit and abdominal wall cavity was excised and vacuum treatment initiated. Total duration of Daptomycin therapy was 3 weeks. While first week skin and wound swabs were still positive for MRSA, all samples were sterile after the second week. Inflammation was monitored by leucocyte count and IL6. The secretion of pus along the driveline ceased, the wound cavity was closed subsequently. After discharge and stop of antibiotics skin and driveline swabs remained negative for MRSA (10 weeks).
authors.forename: Veronika
authors.initials: V
authors.lastname: Walter
authors.forename: Ulrich A
authors.initials: UA
authors.lastname: Stock
authors.forename: Mauricio
authors.initials: M
authors.lastname: Soriano-Romero
authors.forename: Andreas
authors.initials: A
authors.lastname: Schnitzbauer
authors.forename: Anton
authors.initials: A
authors.lastname: Moritz
authors.affiliation: Department Thoracic & Cardiovascular Surgery, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Theodor-Stern-Kai 7, Frankfurt 61590, Germany. Andres.Beiras@kgu.de.
authors.forename: Andres
authors.initials: A
authors.lastname: Beiras-Fernandez
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D017576:Daptomycin / Q000627:therapeutic use; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification; D008875:Middle Aged; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000209:etiology*; D012086:Reoperation; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin